Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CHRS
COHERUS ONCOLOGY, INC.
NASDAQ
$1.42
▲ UP 3.65% (0.05)

KEY STATISTICS

Market Cap$220.16 M
52w High$2.62
52w Low$1.09
Dividend Yield—
Frequency—
P/E-1.28
Volume304.11K
Shares Out.154.50M

COMPANY

LEADERSHIP

Dennis Lanfear
CHIEF EXECUTIVE
Dennis Lanfear

COMPENSATION 2026

Salary$1,026,545
Stock Awards$0
Incentive Plan Pay$869,295
All Other Comp.$12,904
Total$2,736,874

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 6, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
144

PRICE TARGET

Target High$11.00
Target Low$1.05
Target Median$6.00
Target Consensus$6.02

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$15.98M
NOV
5
THU

PRICE

$1.42 ▲ UP 3.65% (+$0.05)
$1.38$1.39$1.41$1.429:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.42

About Coherus Oncology, Inc.

https://www.coherus.com ↗

Coherus Oncology develops and commercializes immunotherapies and biosimilars for cancer and inflammatory diseases, with collaborations and licensing agreements worldwide.

INDUSTRY

Biotechnology

A PRODUCT COHERUS ONCOLOGY, INC. IS KNOWN FOR

LOQTORZI (toripalimab-tpzi)
LOQTORZI (toripalimab-tpzi)

LOQTORZI, FDA-approved in October 2023 as the first treatment for recurrent or metastatic nasopharyngeal carcinoma, marks Coherus' strategic shift from biosimilars to a leading immuno-oncology franchise.

COMPETITORS

COMPETITOR
AZN COMPARE
BMY COMPARE
MRK COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product and Service Other$402K $388K ▼$507K ▲$694K ▲

Revenue by Geography

MapREGIONQ3-2016Q1-2017Q2-2017Q3-2017
UNITED STATES$162.54M — — —
NonUS$298K $161K ▼$1.4M ▲$1.56M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
64
LISTED HERE
11
RANKED BY POSITION SIZE
VTS.AX
0.00% · 5.7M
XSU.TO
0.01% · 3.2M
SCHA
0.00% · 702.7K
PRFZ
0.01% · 210.4K
ZPRR.DE
0.00% · 154.4K
XRSU.L
0.01% · 118.7K
RSSL
0.01% · 62.1K
DFAS
0.00% · 15.1K
BIB
0.01% · 5.5K
FSEG
0.04% · 2.1K
DM
DMRS
0.06% · 2.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
39.12%
HOLDERS
229
TOP 12 OF 229 · RANKED BY POSITION SIZE
Blackrock, Inc.
12.0M sh · $16.8M
Blackrock Inc.
11.8M sh · $20.33M
Vanguard Group Inc
10.3M sh · $16.93M
Tang Capital Management LLC
5.1M sh · $8.36M
Geode Capital Management, LLC
3.7M sh · $5.16M
Samsara Biocapital, LLC
3.4M sh · $4.8M
Kohlberg Kravis Roberts & Co. L.P.
3.0M sh · $4.18M
State Street Corp
2.4M sh · $3.34M
Two Sigma Investments, LP
2.3M sh · $3.89M
Alyeska Investment Group, L.P.
2.3M sh · $3.8M
Cm Management, LLC
2.1M sh · $3.55M
Tiaa Cref Investment Management LLC
2.1M sh · $28.41M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Shri Thanedar
Shri Thanedar
Sale (Full)
2023-01-23

INSIDER TRADES

★
DIRECTOR
Newcomer Lee Nisley
Purchase · 60.0K shares
2026-06-05
★
DIRECTOR
O'Donnell-Tormey Jill
Purchase · 60.0K shares
2026-06-05
★
DIRECTOR
Newcomer Lee Nisley
Purchase · 30.0K shares
2026-06-05
★
DIRECTOR
Ryan Michael Lee
Purchase · 30.0K shares
2026-06-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY

SECTORS PEERS

PEERPRICE
SLS$13.87COMPARE
AVTX$19.27COMPARE
OABI$4.41COMPARE
CCCC$3.82COMPARE
IVVD$0.81COMPARE
TARA$3.94COMPARE
CDXS$1.45COMPARE
IMDX$4.09COMPARE